Replimune REPL
NASDAQ REPL
$15.04 -0.25 (-1.64%)
As of: Sep 4, 2026 · 3:59 PM EDT

Replimune (REPL) Cash from Investing Activities (2017 - 2026)

Replimune (REPL) posted Cash from Investing Activities of $86.5 million for Q1 2026, up 15.16% sequentially from $75.1 million in Q4 2025, and up 1223.45% YoY from $6.5 million in Q1 2025.

Analysis

Replimune (REPL) Cash from Investing Activities (2017 - 2026) Analysis & Trends

Replimune has reported Cash from Investing Activities for 10 years, with the latest figure at $86.5 million in Q1 2026.

  • Quarterly Cash from Investing Activities rose 1223.45% year-over-year to $86.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $310.8 million (up 1406.28% YoY) and the FY2026 annual result came in at $310.8 million, up 1406.28% from the prior year.
  • Cash from Investing Activities grew to $86.5 million in Q1 2026 per REPL's latest filing, from $75.1 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $86.5 million in Q1 2026 and troughed at -$125.1 million in Q4 2022.
  • A 5-year average of $14.0 million and a median of $7.4 million in 2023 frame the typical range for Cash from Investing Activities.
  • The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 832.2% in 2022, then jumped 35130.56% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$125.1 million in 2022, then jumped by 143.13% to $54.0 million in 2023, then plunged by 185.85% to -$46.3 million in 2024, then surged by 262.18% to $75.1 million in 2025, then gained by 15.16% to $86.5 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered $86.5 million, $75.1 million, and $84.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 Replimune 1.46 Bn 1.46 Bn - 49.99 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 49.99 Mn
Mar 31, 2026 86.51 Mn
Dec 31, 2025 75.12 Mn
Sep 30, 2025 84.17 Mn
Jun 30, 2025 65.05 Mn
Mar 31, 2025 -7.70 Mn
Dec 31, 2024 -46.32 Mn
Sep 30, 2024 458,000.00
Jun 30, 2024 29.77 Mn
Mar 31, 2024 23.20 Mn
Dec 31, 2023 53.96 Mn
Sep 30, 2023 12.68 Mn
Jun 30, 2023 7.36 Mn
Mar 31, 2023 -22.75 Mn
Dec 31, 2022 -125.10 Mn
Sep 30, 2022 36,000.00
Jun 30, 2022 5.32 Mn
Mar 31, 2022 -4.33 Mn
Dec 31, 2021 -13.42 Mn
Sep 30, 2021 -11.05 Mn